Abstract
The Runx1 transcription factor, known for its essential role in normal hematopoiesis, was reported in limited studies to be mutated or associated with human breast tumor tissues. Runx1 increases concomitantly with disease progression in the MMTV-PyMT transgenic mouse model of breast cancer. Compelling questions relate to mechanisms that regulate Runx1 expression in breast cancer. Here, we tested the hypothesis that dysregulation of Runx1-targeting microRNAs (miRNAs) allows for pathologic increase of Runx1 during breast cancer progression. Microarray profiling of the MMTV-PyMT model revealed significant downregulation of numerous miRNAs predicted to target Runx1. One of these, miR-378, was inversely correlated with Runx1 expression during breast cancer progression in mice and in human breast cancer cell lines MCF7 and triple-negative MDA-MB-231 that represent early- and late-stage diseases, respectively. MiR-378 is nearly absent in MDA-MB-231 cells. Luciferase reporter assays revealed that miR-378 binds the Runx1 3′ untranslated region (3′UTR) and inhibits Runx1 expression. Functionally, we demonstrated that ectopic expression of miR-378 in MDA-MB-231 cells inhibited Runx1 and suppressed migration and invasion, while inhibition of miR-378 in MCF7 cells increased Runx1 levels and cell migration. Depletion of Runx1 in late-stage breast cancer cells resulted in increased expression of both the miR-378 host gene PPARGC1B and pre-miR-378, suggesting a feedback loop. Taken together, our study identifies a novel and clinically relevant mechanism for regulation of Runx1 in breast cancer that is mediated by a PPARGC1B-miR-378-Runx1 regulatory pathway. Our results highlight the translational potential of miRNA replacement therapy for inhibiting Runx1 in breast cancer.
Similar content being viewed by others
References
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.
Toss A, Cristofanilli M. Molecular characterization and targeted therapeutic approaches in breast cancer. Breast Cancer Res. 2015;17:60.
Ichikawa M, Yoshimi A, Nakagawa M, Nishimoto N, Watanabe-Okochi N, Kurokawa M. A role for runx1 in hematopoiesis and myeloid leukemia. Int J Hematol. 2013;97:726–34.
Scheitz CJ, Tumbar T. New insights into the role of runx1 in epithelial stem cell biology and pathology. J Cell Biochem. 2013;114:985–93.
Hoi CS, Lee SE, Lu SY, McDermitt DJ, Osorio KM, Piskun CM, et al. Runx1 directly promotes proliferation of hair follicle stem cells and epithelial tumor formation in mouse skin. Mol Cell Biol. 2010;30:2518–36.
Heikinheimo K, Kurppa KJ, Laiho A, Peltonen S, Berdal A, Bouattour A, et al. Early dental epithelial transcription factors distinguish ameloblastoma from keratocystic odontogenic tumor. J Dent Res. 2015;94:101–11.
Keita M, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud MC, et al. The runx1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle. 2013;12:972–86.
Wang X, Zhao Y, Qian H, Huang J, Cui F, Mao Z. The mir-101/runx1 feedback regulatory loop modulates chemo-sensitivity and invasion in human lung cancer. Int J Clin Exp Med. 2015;8:15030–42.
Jacques C, Guillotin D, Fontaine JF, Franc B, Mirebeau-Prunier D, Fleury A, et al. DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors. J Clin Endocrinol Metab. 2013;98:E981–9.
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486:405–9.
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353–60.
Chimge NO, Frenkel B. The runx family in breast cancer: relationships with estrogen signaling. Oncogene. 2013;32:2121–30.
Ferrari N, Mohammed ZM, Nixon C, Mason SM, Mallon E, McMillan DC, et al. Expression of runx1 correlates with poor patient prognosis in triple negative breast cancer. PLoS One. 2014;9, e100759.
van Bragt MP, Hu X, Xie Y, Li Z. Runx1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells. Elife. 2014;3, e03881.
Stender JD, Kim K, Charn TH, Komm B, Chang KC, Kraus WL, et al. Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol. 2010;30:3943–55.
Browne G, Taipaleenmaki H, Bishop NM, Madasu SC, Shaw LM, van Wijnen AJ, et al. Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion. J Cell Physiol. 2015;230:2522–32.
Tang W, Yu F, Yao H, Cui X, Jiao Y, Lin L, et al. Mir-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene. 2014;33:2629–38.
Acunzo M, Romano G, Wernicke D, Croce CM. Microrna and cancer—a brief overview. Adv Biol Regul. 2015;57:1–9.
Browne G, Taipaleenmaki H, Stein GS, Stein JL, Lian JB. MicroRNAs in the control of metastatic bone disease. Trends Endocrinol Metab. 2014;25:320–7.
van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. 2015;17:21.
Nana-Sinkam SP, Croce CM. MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use. Genome Biol. 2014;15:445.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–33.
Wilczynska A, Bushell M. The complexity of miRNA-mediated repression. Cell Death Differ. 2015;22:22–33.
Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.
Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769–73.
Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482:347–55.
Le Quesne J, Caldas C. Micro-RNAs and breast cancer. Mol Oncol. 2010;4:230–41.
Berindan-Neagoe I, Monroig Pdel C, Pasculli B, Calin GA. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014;64:311–36.
Iorio MV, Croce CM. Causes and consequences of microRNA dysregulation. Cancer J. 2012;18:215–22.
Arora S, Rana R, Chhabra A, Jaiswal A, Rani V. MiRNA-transcription factor interactions: a combinatorial regulation of gene expression. Mol Genet Genomics. 2013;288:77–87.
Rossetti S, Sacchi N. Runx1: a microRNA hub in normal and malignant hematopoiesis. Int J Mol Sci. 2013;14:1566–88.
Taipaleenmaki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL, et al. Targeting of runx2 by mir-135 and mir-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 2015;75:1433–44.
Liu Z, Chen L, Zhang X, Xu X, Xing H, Zhang Y, et al. Runx3 regulates vimentin expression via mir-30a during epithelial-mesenchymal transition in gastric cancer cells. J Cell Mol Med. 2014;18:610–23.
Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, Lim XY, et al. MicroRNA-130b regulates the tumour suppressor runx3 in gastric cancer. Eur J Cancer. 2010;46:1456–63.
Wang M, Li C, Yu B, Su L, Li J, Ju J, et al. Overexpressed mir-301a promotes cell proliferation and invasion by targeting runx3 in gastric cancer. J Gastroenterol. 2013;48:1023–33.
Lee DY, Deng Z, Wang CH, Yang BB. Microrna-378 promotes cell survival, tumor growth, and angiogenesis by targeting sufu and fus-1 expression. Proc Natl Acad Sci U S A. 2007;104:20350–5.
Ma J, Lin J, Qian J, Qian W, Yin J, Yang B, et al. Mir-378 promotes the migration of liver cancer cells by down-regulating fus expression. Cell Physiol Biochem. 2014;34:2266–74.
Yu BL, Peng XH, Zhao FP, Liu X, Lu J, Wang L, et al. MicroRNA-378 functions as an onco-mir in nasopharyngeal carcinoma by repressing tob2 expression. Int J Oncol. 2014;44:1215–22.
Zhang GJ, Zhou H, Xiao HX, Li Y, Zhou T. Mir-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer. BMC Cancer. 2014;14:109.
Avgeris M, Stravodimos K, Scorilas A. Loss of mir-378 in prostate cancer, a common regulator of klk2 and klk4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. Biol Chem. 2014;395:1095–104.
Wang KY, Ma J, Zhang FX, Yu MJ, Xue JS, Zhao JS. MicroRNA-378 inhibits cell growth and enhances l-ohp-induced apoptosis in human colorectal cancer. IUBMB Life. 2014;66:645–54.
Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle t oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12:954–61.
Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2008;2008:pdb prot4986.
Romano P, Manniello A, Aresu O, Armento M, Cesaro M, Parodi B. Cell line data base: structure and recent improvements towards molecular authentication of human cell lines. Nucleic Acids Res. 2009;37:D925–32.
Benjamini Y, Hochberg Y. Controlling the false discovery rate—a practical and powerful approach to multiple testing. J R Stat Soc Ser B-Methodol. 1995;57:289–300.
Gutierrez S, Javed A, Tennant DK, van Rees M, Montecino M, Stein GS, et al. Ccaat/enhancer-binding proteins (c/ebp) beta and delta activate osteocalcin gene transcription and synergize with runx2 at the c/ebp element to regulate bone-specific expression. J Biol Chem. 2002;277:1316–23.
Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase ii in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:1475–89.
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
Feng J, Liu T, Qin B, Zhang Y, Liu XS. Identifying CHiP-seq enrichment using MACS. Nat Protoc. 2012;7:1728–40.
Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003;163:2113–26.
Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010;32:35–48.
Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13:215.
Kimura H. Histone modifications for human epigenome analysis. J Hum Genet. 2013;58:439–45.
Benayoun BA, Pollina EA, Ucar D, Mahmoudi S, Karra K, Wong ED, et al. H3k4me3 breadth is linked to cell identity and transcriptional consistency. Cell. 2014;158:673–88.
Eichner LJ, Perry MC, Dufour CR, Bertos N, Park M, St-Pierre J, et al. Mir-378(*) mediates metabolic shift in breast cancer cells via the pgc-1beta/errgamma transcriptional pathway. Cell Metab. 2010;12:352–61.
Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597–610.
Bowers SR, Calero-Nieto FJ, Valeaux S, Fernandez-Fuentes N, Cockerill PN. Runx1 binds as a dimeric complex to overlapping runx1 sites within a palindromic element in the human GM-CSF enhancer. Nucleic Acids Res. 2010;38:6124–34.
Speck NA, Terryl S. A new transcription factor family associated with human leukemias. Crit Rev Eukaryot Gene Expr. 1995;5:337–64.
Serpico D, Molino L, Di Cosimo S. MicroRNAs in breast cancer development and treatment. Cancer Treat Rev. 2014;40:595–604.
Hassan MQ, Maeda Y, Taipaleenmaki H, Zhang W, Jafferji M, Gordon JA, et al. Mir-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem. 2012;287:42084–92.
Hassan MQ, Gordon JA, Beloti MM, Croce CM, van Wijnen AJ, Stein JL, et al. A network connecting runx2, satb2, and the mir-23a∼27a∼24-2 cluster regulates the osteoblast differentiation program. Proc Natl Acad Sci U S A. 2010;107:19879–84.
Ben-Ami O, Pencovich N, Lotem J, Levanon D, Groner Y. A regulatory interplay between mir-27a and runx1 during megakaryopoiesis. Proc Natl Acad Sci U S A. 2009;106:238–43.
Zaidi SK, Dowdy CR, van Wijnen AJ, Lian JB, Raza A, Stein JL, et al. Altered runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a mir-24/MKP-7/MAPK network. Cancer Res. 2009;69:8249–55.
Yin JY, Deng ZQ, Liu FQ, Qian J, Lin J, Tang Q, et al. Association between mir-24 and mir-378 in formalin-fixed paraffin-embedded tissues of breast cancer. Int J Clin Exp Pathol. 2014;7:4261–7.
Knezevic I, Patel A, Sundaresan NR, Gupta MP, Solaro RJ, Nagalingam RS, et al. A novel cardiomyocyte-enriched microRNA, mir-378, targets insulin-like growth factor 1 receptor: implications in postnatal cardiac remodeling and cell survival. J Biol Chem. 2012;287:12913–26.
Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer. 2015;14:43.
Pande S, Browne G, Padmanabhan S, Zaidi SK, Lian JB, van Wijnen AJ, et al. Oncogenic cooperation between pi3k/akt signaling and transcription factor runx2 promotes the invasive properties of metastatic breast cancer cells. J Cell Physiol. 2013;228:1784–92.
Chang YY, Kuo WH, Hung JH, Lee CY, Lee YH, Chang YC, et al. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. Mol Cancer. 2015;14:36.
Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiu X, et al. Hsa-mir-125a-3p and hsa-mir-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer. 2010;10:318.
Guo L, Lu Z. The fate of miRNA* strand through evolutionary analysis: implication for degradation as merely carrier strand or potential regulatory molecule? PLoS One. 2010;5, e11387.
Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, et al. Gata-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell. 2008;13:141–52.
Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12:847–65.
Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol. 2013;31:577.
Bader AG. Mir-34—a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.
Acknowledgments
This work was supported by the National Cancer Institute (Nos. P01 CA082834 and R03 CA167726), National Institute of Arthritis and Musculoskeletal and Skin Diseases (No. R01 AR039588), National Institute of Dental and Craniofacial Research (No. R37 DE012528), Pfizer (WS2049100), and grants from the University of Vermont Cancer Center and Lake Champlain Cancer Research Organization. The microarray research reported was supported by the National Institute of General Medical Sciences (No. P20 GM103449). The authors thank all members of our laboratories, especially Philip W. L. Tai, for valuable suggestions throughout the study. The authors are grateful to the UVM Cancer Center Advanced Genome Technologies Core, supported by UVM Cancer Center, Lake Champlain Cancer Research Organization, and the UVM College of Medicine for data pertaining to cell line authentication, as well as the Vermont Genetics Network Microarray Facility for miRNA target preparation, hybridization, and scanning processing. The authors are also grateful to the Molecular Bioinformatics Shared Resource of the University of Vermont College of Medicine for microarray data analysis. Finally, the authors thank the Advanced Genome Technologies Core Massively Parallel Sequencing Facility for sequencing data. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None
Ethical approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Rights and permissions
About this article
Cite this article
Browne, G., Dragon, J.A., Hong, D. et al. MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells. Tumor Biol. 37, 8825–8839 (2016). https://doi.org/10.1007/s13277-015-4710-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-015-4710-6